@article{oai:yamanashi.repo.nii.ac.jp:00003141,
 author = {NAKAGOMI, Hiroshi and IWASAKI, Masaru and TAKANO, Kunio and MATSUKAWA, Tetsunosuke and UENO, Akira and UMEKITA, Nobutaka},
 issue = {3},
 journal = {山梨医科大学雑誌, 山梨医科大学雑誌},
 month = {},
 note = {Since 1986, we have been investigating repetitive intraportal administration of anticancer agents as prophylaxis for liver metastasis after gastrointestinal cancer surgery. Intraportal mitomycin C (MMC: 4 mg) was given on the day of operation and on postoperative days 1-6. A preliminary pharmacokinetic study of intraportal MMC administration was performed in a rabbit model. A high first-pass extraction ratio was found at doses of 0.05 and 0.1 mg/kg, and it decreased at the higher doses of 0.2 and 0.4 mg/kg. The clinical dose of 4 mg corresponded to 0.05-0.1 mg/kg in the rabbit model and was considered to be within the optimal dose range. The side effects and clinical outcome for patients treated with intraportal MMC were compared with those for a control group. The controls included an MMC (+) group that received intravenous MMC, and a MMC (-) group that did not. The intraportal MMC group showed less toxicity compared with the MMC (+) group and a prospective effect on survival and liver metatstasls. These results suggested that our schedule for repetitive intraportal MMC was adequate.},
 pages = {89--95},
 title = {<Original Article> Clinical Trial of Repetitive Portal Administration of Anticancer Drug as a Prophylactic Modality for Liver Metastasis - A Pilot Study of the Optimal Dosage and Reduced Toxicity -},
 volume = {7},
 year = {1992}
}